Initiatives and support for human medicines development in the EU and US

Setting the scene: use regulatory support early, not as an afterthought

Companies developing novel human medicines for rare and/or serious conditions can access a range of regulatory initiatives in the European Union (EU) and United States of America (US). These schemes are designed to provide earlier interaction with regulators, potential fee reductions, and – in some cases – to accelerate development and provide a faster review route.

Clear takeaway: assess strategy early so the development plan captures the maximum regulatory, financial and strategic benefit.

Options available: matching the right scheme to the product

The most relevant route will depend on the product, the condition, the regulatory region, the developer’s company structure and the level of clinical evidence already available. The options below can be used individually or, where appropriate and depending on the region, in combination.

1. Orphan designation / orphan drug designation (ODD)

What it is

Orphan designation can be requested pre-authorisation in both the EU and US for medicines targeting rare diseases or conditions. In the EU, the candidate drug must be intended for a life-threatening or chronically debilitating condition with no, or unsatisfactory, treatment options and which affects fewer than 5 in 10,000 people in the EU. In the US, companies can apply to the Food and Drug Administration (FDA) for ODD where fewer than 200,000 people are affected by the disease.

Why it matters

• Can provide access to specific scientific advice for orphan medicines in the EU, known as protocol assistance.
• Can unlock fee reductions and potential market exclusivity if the medicine is ultimately authorised.
• Can also be requested in both regions based on lack of return on investment, although prevalence is usually the basis for designation.

Clear takeaway: for rare disease products, ODD should usually be explored as an option as early as possible.

2. SME status and small business fee waivers

What it is

Small to medium-sized companies can apply for micro, small and medium-sized enterprise (SME) status in the EU, either through their own EU entity or via an EU consultancy that holds SME status and can append status for other companies. Eligibility depends on employee count, and annual turnover or balance-sheet total; company structure is important here, for example whether the company is a wholly-owned subsidiary of a larger organisation.

What it gives you

• SME status in the EU can provide important fee reductions.
• A small company developing a medicine for an orphan disease should generally pursue both ODD and SME status in the EU, as this can provide a 100% fee reduction for certain procedures. · In the US, a small business submitting its first human drug application may be eligible for an FDA application-fee waiver if it meets the relevant size and product criteria; the waiver is valid for one year from issue.

Clear takeaway: combining EU SME status with ODD can reduce regulatory fee costs.

3. Enhanced regulatory interaction for unmet medical needs

EU route: PRIME

The European Medicines Agency’s PRIME (priority medicines) scheme provides early support and enhanced advice, including expedited scientific advice and a submission-readiness meeting. PRIME is focused on medicines that target unmet medical need, either where no treatment exists or where the product could offer a significant therapeutic advantage over existing treatments. Developers of orphan medicines should therefore consider whether PRIME may be appropriate.

Applicants usually need to demonstrate meaningful improvement in clinical outcomes, typically supported by preliminary clinical evidence or proof of concept.

US routes: Breakthrough Therapy and Fast Track

In the US, Breakthrough Therapy designation can expedite development and review for drugs treating serious conditions that may demonstrate substantial improvement over current therapies. Fast Track designation may be available for drugs for serious conditions that have the potential to address unmet medical needs. Both routes provide enhanced FDA guidance and support, as well as potential eligibility for priority review of a new drug application.

Clear takeaway: PRIME, Breakthrough Therapy and Fast Track can provide enhanced support during development and may accelerate the process, but the evidential threshold and qualifying criteria are region-specific.

4. ATMP classification and RMAT designation

ATMP classification in the EU

For products based on genes, tissues or cells, companies developing medicines for human use may seek classification as an advanced therapy medicinal product (ATMP) in the EU. This helps clarify whether the product is an ATMP and can resolve potential borderline issues with other areas, such as medical devices, before pursuing further procedures such as scientific advice or ODD.

Important caveat

ATMP classification alone does not provide the incentives available through schemes such as ODD or SME status.

RMAT designation in the US

There is no direct equivalent ATMP-classification process in the US. However, a drug may be eligible for Regenerative Medicine Advanced Therapy (RMAT) designation, which covers cell therapies and human cell and tissue products. RMAT requires preliminary clinical evidence showing the potential to address unmet medical needs for a serious or life-threatening condition.

Clear takeaway: ATMP classification in the EU is useful for regulatory clarity, but it should not be confused with schemes such as ODD or SME status.

Key takeaways for biotech and pharma

• Consider relevant EU and US schemes as early as possible in development.
• Do not assume that similar initiatives have identical criteria across regions.
• For rare disease products, assess ODD and EU SME status together to maximise fee-reduction opportunities.
• For medicines addressing high unmet need, consider whether PRIME, Breakthrough Therapy, Fast Track or RMAT may be available.
• For gene, tissue or cell-based products, consider whether ATMP classification is needed to clarify the EU regulatory pathway.
• Use regulatory interactions strategically: the aim is not just to obtain a designation, but to build a stronger, more efficient development plan.

Bottom line: plan early, combine intelligently

The EMA and FDA offer support schemes but the qualification criteria, timing and benefits differ. Early, structured assessment helps companies avoid missed incentives, reduce unnecessary costs and position their development programme more effectively.

Need regulatory strategy support? Contact tranScrip to discuss your programme needs.